Null Alleles of the COL5A1 Gene of Type V Collagen Are a Cause of the Classical Forms of Ehlers-Danlos Syndrome (Types I and II)  by Schwarze, Ulrike et al.
Am. J. Hum. Genet. 66:1757–1765, 2000
1757
Null Alleles of the COL5A1 Gene of Type V Collagen Are a Cause of the
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Ehlers-Danlos syndrome (EDS) types I and II, which comprise the classical variety, are well characterized from
the clinical perspective, but it has been difﬁcult to identify the molecular basis of the disorder in the majority
of affected individuals. Several explanations for this failure to detect mutations have been proposed, including
genetic heterogeneity, failure of allele expression, and technical difﬁculties. Genetic heterogeneity has been
conﬁrmed as an explanation for such failure, since causative mutations have been identiﬁed in the COL5A1,
COL5A2, and tenascin X genes and since they have been inferred in the COL1A2 gene. Nonetheless, in the
majority of families with autosomal dominant inheritance of EDS, there appears to be linkage to loci that
contain the COL5A1 or COL5A2 genes. To determine whether allele-product instability could explain failure
to identify some mutations, we analyzed polymorphic variants in the COL5A1 gene in 16 individuals, and
we examined mRNA for the expression of both alleles and for alterations in splicing. We found a splice-site
mutation in a single individual, and we determined that, in six individuals, the mRNA from one COL5A1
allele either was not expressed or was very unstable. We identiﬁed small insertions or deletions in ﬁve of these
cell strains, but we could not identify the mutation in the sixth individual. Thus, although as many as one-
half of the mutations that give rise to EDS types I and II are likely to lie in the COL5A1 gene, a signiﬁcant
portion of them result in very low levels of mRNA from the mutant allele, as a consequence of nonsense-
mediated mRNA decay.
Introduction
The classical forms of Ehlers-Danlos syndrome (EDS
type I [MIM 130000] and EDS type II [MIM 130010])
are characterized by very soft and hyperextensible skin,
easy bruising, “cigarette-paper” scars, and marked
small- and large-joint laxity (Beighton 1993; Steinmann
et al. 1993; Beighton et al. 1998). These forms of EDS
are inherited in an autosomal dominant fashion, but new
mutations are common. The altered mechanical prop-
erties of skin and ligaments made alterations in the con-
stitutive “collagen” a strong candidate(s) for the location
of the basic defect (Grahame and Beighton 1969). The
results of morphological studies of skin from affected
individuals demonstrated that collagen ﬁbrils in the der-
mis (which comprise largely type I collagen) were larger
than normal and that there was a population of aggre-
gated ﬁbrils (Vogel et al. 1979; Hausser and Anton-Lam-
precht 1994). The ﬁndings of biochemical studies of cul-
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tured ﬁbroblasts from affected individuals were
remarkably unrevealing, with the exception of the iden-
tiﬁcation of rare individuals who appeared to be ho-
mozygous for “null” COL1A2 alleles (Sasaki et al.
1987; Hata et al. 1988). In those families, the phenotype
appeared to be the consequence of a recessive mutation.
Thus, type I collagen genes were not good candidates
for mutations in the dominantly inherited phenotypes of
EDS. The results of directed linkage studies in families
with autosomal dominant inheritance of EDS type I then
excluded type I collagen genes as well as several other
genes that encode extracellular matrix proteins (Words-
worth et al. 1985, 1991; Sokolov et al. 1991).
Studies done using polymorphic markers in the
COL5A1 gene, which is located at chromosome 9q34
and which encodes the proa1(V) chains of type V
collagen, provided evidence that EDS type II (Lough-
lin et al. 1995) and mixed EDS type I/II in the same
family (Burrows et al. 1996; Burrows et al. 1997)
were linked to that locus. In some families, linkage
to COL5A1 (Greenspan et al. 1995) or to COL5A1
and COL5A2 (Wenstrup et al. 1996), the latter of
which encodes the proa2(V) chains of type V colla-
gen, could be excluded. The ﬁndings from biochem-
ical analysis of type V collagen molecules synthesized
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by cultured ﬁbroblasts supported the concept that ab-
normalities of these proteins contributed to the phe-
notype of EDS type I or II (Nicholls et al. 1994). In
one child with EDS type I and an X/9 chromosomal
translocation, the breakpoint occurred within intron
24 of the COL5A1 gene at chromosome 9q34 (To-
riello et al. 1996). No protein product of the fusion
gene was identiﬁed. Deletions that resulted from
exon-skipping mutations in either the region of the
COL5A1 gene that encodes the carboxyl-terminal
propeptide (Wenstrup et al. 1996) or the triple-helical
domain (Nicholls et al. 1996; De Paepe et al. 1997;
Burrows et al. 1998), or a point mutation that
changed a cysteine to serine in the carboxyl-terminal
propeptide each resulted in the EDS type I or II phe-
notype (De Paepe et al. 1997). More recently, point
mutations in the COL5A2 gene that produced single
amino-acid substitutions (G934R) (Richards et al.
1998) or exon skipping (Michalickova et al. 1998)
in the triple-helical domain were identiﬁed in indi-
viduals with EDS type I or II.
The coding sequences of both COL5A1 and
COL5A2 have been searched extensively, but the yield
of identiﬁed mutations has been surprisingly small. A
study of 28 affected individuals identiﬁed only four mu-
tations in the two genes (two mutations were found in
each gene) (Michalickova et al. 1998). The possibility
that other genes might be involved was raised by linkage
studies that appeared to exclude both genes (Wenstrup
et al. 1996) and by the identiﬁcation of a deletion of
one allele of tenascin X, adjacent to the 21-hydroxylase
gene (Burch et al. 1997), in an adolescent with EDS and
21-hydroxylase deﬁciency. Most analyses of COL5A1
and COL5A2 coding sequences have been done with
the use of mature mRNA obtained from cultured ﬁbro-
blasts—a strategy that will identify mutations in stable
and abundant mRNA species.
Although missense and splice-site mutations in both
type V collagen genes can cause the classical EDS type
I and II phenotypes, it is plausible that other mutations
in the genes also play a role. The chromosomal trans-
location resulted in failure to synthesize a detectable
protein product from the affected COL5A1 allele,
which, even if expressed, would lack the chain-assembly
region of the carboxyl-terminal propeptide (Toriello et
al. 1996). The mutation that resulted in deletion of the
sequence encoded by exon 65 of the COL5A1 gene
removed a domain that is predicted to function in chain-
chain interaction during molecular assembly (Micha-
lickova et al. 1998). Together, these examples suggest
that other mutations that diminish the amount of
proa1(V) should result in the EDS type I or II phe-
notypes.
To test this hypothesis, we selected cells from 16 in-
dividuals with histories and clinical ﬁndings character-
istic of EDS type I or II, examined mRNA for the ex-
pression of both alleles of COL5A1, and, in 5 of the 6
individuals whose cells expressed only one allele, iden-
tiﬁed the causative mutations. On the basis of the results
of the present study, it appears that mutations that cause
premature-termination codons in the COL5A1 tran-
script and therefore lead to “nonsense-mediated decay”
(Maquat 1995; Frischmeyer and Dietz 1999) of the al-
tered allele are common causes of the classical forms of
EDS.
Material and Methods
Clinical Data and Criteria for Inclusion
The clinical records of individuals whose cells had
been provided for analysis of collagen abnormalities and
who had a diagnosis of EDS were reviewed. Of these
individuals, 16 were selected for screening because they
had clinical ﬁndings compatible with the diagnosis of
EDS type I or II (the classical types in the revised no-
menclature) (Beighton et al. 1998). The clinical ﬁndings
are summarized in table 1. All samples were obtained
with appropriate consent.
Cell Culture and Isolation of RNA and DNA
Cells were cultured as previously described, and the
procollagen and collagen molecules synthesized by these
cells were analyzed after labeling with [3H]-proline and
SDS-PAGE separation of proteins in the medium and the
cell layer (Bonadio et al. 1985). All cells synthesized
normal amounts of procollagen types I and III, which
had normal electrophoretic mobilities and were secreted
normally. The chains of type V collagen were apparent
on the gels, but no speciﬁc alterations could be identiﬁed.
RNA and DNA were isolated from the cells by standard
methods (Sambrook et al. 1989).
Analysis of cDNA from COL5A1 and COL5A2 and of
Genomic DNA Fragments of COL5A1
Complementary DNA was synthesized from the total
cellular RNA, and primers from the coding sequences
of COL5A1 (Greenspan et al. 1991) and COL5A2
(Emanuel et al. 1985; Weil et al. 1987) were used to
amplify six and ﬁve overlapping fragments, respectively,
of the full length of each product. The primers that were
used are shown in table 2. The fragments were separated
on 6% polyacrylamide gels.
Genomic DNA from each patient was used as the
substrate to amplify individual exons (with the ex-
ception of exon 1) from the COL5A1 gene. The
COL5A1 gene comprises 66 exons, of which 65 are
distributed over ∼150 kb; the ﬁrst intron is 1500 kb
in length (Takahara et al. 1995). Each fragment was
analyzed by separation on mutation-detection-en-
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Table 1
Clinical Features of Patients with EDS Types I and II
PATIENT AND
(SEX/AGE [years]b)
CLINICAL FEATURESa
Family
History
Premature
Birth
Skin Soft,
Velvety, and
Hyperextensible
Scars Wide
and Atrophic
Joint
Hypermobility
Easy
Bruising
Referral
Diagnosisc
P1 (M/17)  NA  NA   I (?)
P2 (M/13)  NA  NA  NA I (?)
P3 (M/39)       II
P4 (F/32) NA NA     II
P5 (F/NA) NA NA NA NA NA NA II
P6 (F/4) NA NA     I
P7 (F/36) NA NA  NA   EDS
P8 (F/4)  () 32 wk     I
P9 (F/2)  NA NA    EDS
P10 (M/25) NA NA  NA   II
P11 (M/14)   () Friable  () Small  I (?)
P12 (M/6)    NA   II (?)
P13 (F/14) NA NA     II
P14 (M/5) Adopted NA     I
P15 (F/14)       I (?)
P16 (M/57) NA NA     I/II
NOTE.—NA = not available.
a Plus sign () denotes that the trait was present; minus sign (), the trait was absent.
b Age at clinical diagnosis of classical EDS.
c EDS type.
hancement (MDE) gels, to identify heteroduplexes.
The sequences of the intron primers used are con-
tained in table A1 in the Appendix, which appears
only in the electronic version of the Journal. The full
genomic structure of the COL5A2 gene has not been
published, but the results of analysis of the 5′ coding
region suggest that the gene is similar to other ﬁbrillar
collagen genes (COL1A1, COL1A2, and COL3A1)
and, thus, should have 50–52 exons (Truter et al.
1993).
Four polymorphic sites in the COL5A1 gene were
analyzed in genomic DNA from each affected individual,
by use of intron-based genomic primers. Fragments were
ampliﬁed, were cleaved with the appropriate restriction
enzyme, and were separated by means of PAGE. The
polymorphic variants used were a PstI site in exon 5
(Cappa et al. 1995), a DpnII site in exon 66, and a BstUI
site in exon 66 (Greenspan and Pasquinelli 1994). A
single-nucleotide polymorphism in exon 58 (nucleotide
4482C/G; U. Schwarze, unpublished data) was assayed
as a BslI site, with the use of a mismatch primer to create
the site. BslI cleaves the sequence 5′-CCN5N2GG-3
′ after
N5. The mismatch primer sequence usedwas 5
′-CAGGC-
CTGATCGGGCTCATCCGT-3′, in which C is usually
G. In the product 5′-CAGGCCTGATCGGGCTCA-
TCCGTCCTCCGG)..-3′, the enzyme BslI cleaved
when the penultimate nucleotide (position 4482 of the
coding mRNA) was G. The antisense primer used in
cDNA was exon 62A (table 2), and the genomic primer
was in intron 58 (see table A1 in the Appendix, which
appears only in the electronic version of the Journal).
DNA-Sequence Determination
Aberrant bands identiﬁed by analysis of cDNAs from
the COL5A1 gene were cut from polyacrylamide gels,
were reampliﬁed, and were puriﬁed (with QIA quick-
spin columns) for sequence determination on the ABI
310 genetic analyzer using Big Dye Terminator Cycle
Sequencing Ready Reaction Kit chemistry (PE Biosys-
tems). Products of genomic ampliﬁcation that had het-
eroduplexes identiﬁed by MDE gel electrophoresis were
puriﬁed by means of column chromatography (withQIA
quick-spin columns) and were sequenced on the ABI 310
genetic analyzer (PE Biosystems).
Electron Microscopy
A skin sample available from one patient (patient
P10) was prepared for electron microscopy as previ-
ously described and then was viewed on the Phillips
420 scope in transmission mode (Smith et al. 1992).
Fibril diameter and spacing were analyzed after the
images were scanned.
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Table 2
Primers in cDNA Used to Amplify Large Fragments of the COL5A1 and COL5A2
Coding Regions
Primera
Primer
Locationb
Primer Sequence
(5′r3′)
Size
(bp)
COL5A1:
Exon:
1S 7 GTCCATACCCGCTGGAAAGCGCGCA 1,026
7A 1032 CTCACTGGGCACGTAGTCATAGTCC
5S 703 GATTACTGTGAGCACTACAGCCCTG 1,167
17A 1869 TTGTCCAGGCATTCCTCTGGCTCCA
13S 1639 CAAGCCATTCTCCAGCAGGCCA 1,009
31A 2647 CCTTTGGTCCTTGTCTTCCTGGAT
27S 2361 CTACCCAGGTCCTCGAGGAGTCAA 1,483
48A 3843 CACTGCACCAGGGTTTCCTATTCC
46S 3631 CAGAAAGGTGATGAAGGTCCCAGA 1,183
62A 4813 CGTAGTCCACGTAGTTCTCGCCATT
60S 4620 TCCAAAAGGTGCTAAGGGCTCCT 943
3′-UTR-A 5562 TGCTGAGGTACGAGGTTGCTCTC
COL5A2:
A 78 CAGCTGACTTCATGGTGCTA 1,001
B 923 TCAAGACCTTTGTGTCCTCGG
C 793 GAAGATGGTGAACCTGGCAGA 1,108
D 1900 CTCCAGGATTTCCTGCTTCTC
E 1721 ATCCTGGTGTTCAAGGTCCTG 1,193
F 2913 ATCTTCTCCTGGGTCCCCTTT
G 2677 AAAGGTGGTCGAGGAACCCAA 1,101
H 3777 GTTTTTGTCATCAGGAGCCGC
I 3485 GTGCTGGAATCCCTGGACCAT 947
J 4431 CACAGGAGCAAGATCTATGAT
a The primer sets 13–31, 27–48, 46–62, and 60–3′-UTR were previously published by
Nicholls et al. (1996).
b ForCOL5A1 andCOL5A2, location is in reference to the A of the initiatormethionyl
ATG as nucleotide 1.
Results
A Single, Stable COL5A1 Allele in Cells from Six
Patients with EDS Type I or II
Samples of genomic DNA from 16 individuals with
EDS type I or II were analyzed for heterozygosity of
expressed COL5A1 markers. All but one individual
were heterozygous for at least one marker, and six in-
dividuals were hemizygous in cDNA. Patients P8 and
P11 were heterozygous for a PstI polymorphic marker
in exon 5 (ﬁg. 1A). When cDNA ampliﬁed from exon
1 to exon 7—the interval that contained the single poly-
morphic PstI site—was digested with the enzyme, in the
sample from patient P8, the abundant species was the
() allele, although there was a very small amount of
the () allele present (ﬁg. 1A). The cDNA sample from
patient P11 contained only the () allele. Patients P4
and P6 were heterozygous for the DpnII polymorphic
site in exon 66 (ﬁg. 1B). When cDNA ampliﬁed using
primers in exon 65 and 66 was digested with the enzyme,
only the () allele was stable from both patients (ﬁg.
1B). Patients P1 and P10 were heterozygous for the
BstUI polymorphic site in exon 66 (ﬁg. 1C). When
cDNA ampliﬁed with the use of primers in exon 65 and
66 was digested with the enzyme, only the () allele was
stable from both patients (ﬁg. 1C).
Exon 15 Skip in a Rare Product in One Patient with
EDS Type I
RNA isolated from all 16 individuals was used to
synthesize cDNA, which was then ampliﬁed in six and
ﬁve overlapping fragments for the COL5A1 and the
COL5A2 coding sequences, respectively, and the prod-
ucts were separated on 6% polyacrylamide gels. This
strategy can identify heteroduplexes formed when even
very small amounts of mRNA with insertions or dele-
tions are present (Schwarze et al. 1999). The product of
the second and third fragments (exons 5–17 and 13–31,
respectively) in the COL5A1 mRNA from one patient
(patient P16) had a small amount of an additional frag-
ment that ran faster than the normal fragment (ﬁg. 2).
The sequence of the smaller fragment indicated that it
was missing all of exon 15, and the genomic sequence
showed an IVS1411TrA transversion (cagacattaaca-
cacaccatgtctccctagGGT, in which the boldfaced a at21
is a potential branch point and the t at 11 is changed
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Figure 1 Demonstration of loss of heterozygosity, for one allele
of the COL5A1 gene, in ﬁbroblasts from six patients with EDS type
I or II. A, Heterozygosity for the exon 5 PstI polymorphic site in the
genomic DNA (left) of patients P8 and P11. In the cDNA from patient
P8, a small amount of the () allele is apparent and is probably en-
hanced by heteroduplex formation. The cDNA from patient P11 con-
tained only the () allele. B, Heterozygosity for the exon 66 DpnII
polymorphic site in the genomic DNA (left) of patients P4 and P6. In
the cDNA (right) from patient P4, a small amount of the () allele
was apparent, but none was apparent in the sample from patient P6.
C, Heterozygosity for the exon 66 BstUI polymorphic site in the ge-
nomic DNA (left) of patients P10 and P1. When cDNA ampliﬁed with
the use of primers in exons 65 and 66 was digested with the enzyme,
only the () allele was stable from both patients.
Figure 2 Ampliﬁcation of the coding regions encompassed by
exons 13–31 of the COL5A1 gene, from a control individual and from
one patient (patient P16). In the cDNA from patient P16, a lighter
band is seen that migrates faster than the normal band; in addition,
a faint heteroduplex (designated by “H”) is also apparent.
to a). This mutation does two things. First, it creates a
run of three consecutive purines in the middle of the
polypyrimidine tract of an already pyrimidine-poor
stretch; this should decrease splicing efﬁciency. Second,
it creates a new acceptor sequence that could be used
in conjunction with a compatible branch point ∼20 nu-
cleotides upstream. If used, this acceptor site would add
9 nucleotides to the mRNA, in which the third codon
would be TAG, which is a termination codon. We
searched for this product in nuclear RNA, including
RNA isolated after 6-h incubation with cycloheximide
to inhibit nonsense-mediated decay; however, we were
unable to identify it. Patient P16 was homozygous at all
expressed polymorphic loci, so we could not determine
(1) whether the low amount of product indicated that
a second, highly unstable product was also formed or
(2) whether the product of the mutant allele was usual-
ly normal and the exon-skipped product was in low
abundance.
Identiﬁcation of Sequence Variants That Led to
Unstable mRNA
Because analysis of the cDNA in all 15 of the other
patients failed to demonstrate heteroduplexes, we then
analyzed genomic DNA from those individuals whose
mature mRNA contained only one expressed allele. Ex-
ons 2–66 of the COL5A1 gene were ampliﬁed from
genomic DNA obtained from each of the patients in
whom loss of heterozygosity could be demonstrated.
Each fragment was screened using the MDE gel system,
to detect heteroduplexes indicative of sequence variation
between the two alleles. The products from each frag-
ment that demonstrated variants were sequenced with
use of the ABI 310 automated sequencer (PE Biosys-
tems). There were ﬁve to eight variants per patient (data
not shown). A frameshift mutation was identiﬁed in ﬁve
of the six individuals in whom we could demonstrate
loss of heterozygosity at the mRNA level. In each in-
stance, a single-nucleotide insertion or deletion produced
a shift in the reading frame and resulted in a downstream
stop codon separated by eight or more introns from the
constitutive termination codon (ﬁg. 3). When cDNAwas
sequenced in these individuals, through the region of the
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Figure 3 Mutations identiﬁed in genomic DNA from ﬁve pa-
tients in whom one COL5A1 allele was not stable in mRNA.
Figure 4 A, Electron micrograph of collagen ﬁbrils in skin from
patient P10 (A), compared with ﬁbril diameters of a sample from a
control individual (B). The ﬁbrils from the patient are larger and more
irregular. In addition, there are composite ﬁbrils (arrows).
genomic insertion or deletion, only the normal allele was
identiﬁed (not shown).
In the genomic DNA from the sixth individual (patient
P8), we found a single GrA transition at position 20,
in intron 49 of one allele of theCOL5A1 gene. Although
this transition changes a G in a GGG triplet that could
function as an intron-splicing enhancer (McCullough
and Berget 1997), we found the same change in one
other individual who expressed both copies of the
COL5A1 gene in equal amounts. If the mutation
changed the speciﬁcity of the splicing and permitted use
of a downstream donor site, the use of the donor site
embedded within the constitutive donor site would add
four nucleotides to the mRNA and would result in a
downstream stop codon. We searched for evidence of
this product in nuclear and cytoplasmic RNA, both with
and without the addition of cycloheximide to stabilize
the abnormal product. We could not ﬁnd any evidence
of the product, and we observed no heteroduplexes after
ampliﬁcation of the cDNA in this region and separation
of the products on polyacrylamide gels—a sensitive test
for the presence of small amounts of product. Thus, we
remain uncertain about the molecular basis for the ab-
sence of one allelic product in the sixth individual.
Alteration of Collagen-Fibril Architecture in Skin from
an Individual with a COL5A1 Null Mutation
A skin-biopsy specimen from patient P10 was ﬁxed
in glutaraldehyde, embedded in Epon, sectioned, and
examined by transmission electron microscopy. Fibrils
were larger and less compact, and composite ﬁbrils were
apparent in the skin (ﬁg. 4). These ﬁndings are char-
acteristic of ﬁndings in the skin of individuals with EDS
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types I and II (Vogel et al. 1979; Holbrook and Byers
1989; Hausser and Anton-Lamprecht 1994). Similar
structures have been identiﬁed in skin from individuals
with EDS type I or II and exon-skipping mutations in
COL5A1 (Burrows et al. 1998) and COL5A2 (Nicholls
et al. 1996; Michalickova et al. 1998), or a mutation in
the carboxyl-terminal propeptide of the proa1(I) chain
encoded by COL5A1 (De Paepe et al. 1997).
Discussion
Mutation analysis in individuals with EDS types I and
II has been frustratingly unproductive, despite the ﬁnd-
ing that many families appear likely to have mutations
in either the COL5A1 or COL5A2 gene. Analysis of the
expressed coding sequences of these genes has identiﬁed
mutations in the minority of cases—that is, in probably
!20% of patients, overall, from several studies. Until
now, it has not been clear whether failed detection was
a consequence of analysis of the wrong gene, imperfect
technique, or failure of allele expression or stability. In
the present study, we have demonstrated that a signiﬁ-
cant proportion of individuals with the EDS type I and
II phenotypes have premature-termination codons
within the coding sequence of the COL5A1 gene. These
mutations lead to mRNA instability, presumably by
means of the mechanism of nonsense-mediated mRNA
decay (Maquat 1995; Frischmeyer and Dietz 1999).
We identiﬁed mutations in genomic DNA from ﬁve
of the six cell strains in which we could demonstrate
that the product of one COL5A1 allele was absent from
mRNA. Despite ampliﬁcation of and a search for var-
iants in all the exons of patient P8, we were able to ﬁnd
only one possibly relevant variation: a GrA transition
in intron 49 in the ﬁrst of several GGG motifs down-
stream from the donor site. Although mutations in such
motifs can lead to aberrant splicing (McCullough and
Berget 1997; McCarthy and Phillips 1998), this did not
appear to occur in this instance, since we identiﬁed the
same alteration in another individual who expressed
both COL5A1 alleles in equal abundance.
It is possible that promoter mutations in COL5A1
could alter allele expression, although such mutations
are uncommon causes of human disorders. We have not
completed screening of the coding sequences of the
COL5A1 and COL5A2 genes, nor have we identiﬁed,
in COL5A2, useful polymorphic variants with which
to assess allele expression and stability. Although the
majority of causative mutations appear to be in these
two genes, we cannot yet deﬁne the precise proportion
that could be in other genes. It is clear, nonetheless, that
COL5A1 null alleles signiﬁcantly contribute to the mo-
lecular etiology of EDS types I and II.
Throughout vertebrate tissues, type V collagen is
widely distributed in the form of an a1(V)2a2(V) het-
erotrimeric molecule. Other reported forms of type V
collagen include an a1(V)3 homotrimer that is produced
by a line of hamster cells (Haralson et al. 1980) and
that may also exist in normal tissues (Kumamoto and
Fessler 1980; Moradi-Ameli et al. 1994) and an a1(V)/
a2(V)/a3(V) heterotrimer that is isolated from human
placenta and that contains the poorly characterized
a3(V) chain (Rhodes and Miller 1981; Niyibizi et al.
1984). The a1(V)2a2(V) heterotrimer is synthesized by
cultured dermal ﬁbroblasts at relatively low levels (com-
pared with levels for collagen types I and III), as a pre-
cursor molecule containing two proa1(V) chains and a
single proa2(V) chain, which are encoded by COL5A1
andCOL5A2, respectively. The proa1(V) and proa2(V)
chains have amino- and carboxyl-terminal propeptides
that are proteolytically processed to yield the mature
a1(V)2a2(V) molecule. While it is uncertain whether
ﬁbrils composed solely of type V molecules are formed
in vertebrate tissues (Fessler and Fessler 1987), it is clear
that a1(V)2a2(V) molecules can combine with the much
more abundant type I collagen to form heterotypic ﬁ-
brils (Birk et al. 1988; Linsenmayer et al. 1993)—that
is, ﬁbrils that contain more than one type of collagen,
typical of those in skin. The results of in vitro ﬁbril-
logenesis experiments, in which the amount of type V
collagen is varied, show an inverse correlation between
the diameter of heterotypic ﬁbrils of type I and V col-
lagens and the relative amount of type V collagen. In
other words, the greater the relative amount of type V
collagen, compared with that of type I collagen, the
smaller the ﬁbril (Linsenmayer et al. 1993). The results
of such experiments have led to the suggestion that at
least one function of a1(V)2a2(V) heterotrimers is to
regulate the size and shape of heterotypic ﬁbrils.
In contrast to the mature chains of collagen types I
and III, the mature a1(V) chain of the a1(V)2a2(V)
collagen molecule retains a signiﬁcant portion—several
hundred amino acids in length—of the large amino-
terminal peptide of the proa1(V) precursor (Linsen-
mayer et al. 1993). The results of analyses of heterotypic
ﬁbrils indicate that type V collagen is located through-
out the ﬁbril (Birk et al. 1988). However, the amino-
terminal–extended structure of the a1(V) chain appears
to protrude beyond the surface of the heterotypic ﬁbrils,
where it has been proposed to regulate the diameter of
the ﬁbril by hindering further addition of type I collagen
monomers (Linsenmayer et al. 1993). The latter effect
may be the result of steric hindrance, or it may involve
the highly charged nature of the residual a1(V) amino-
terminal sequence, which contains a number of sulfated
tyrosines (Fessler and Fessler 1987). The a1(V) amino-
terminal sequence, which projects onto the surface of
ﬁbrils, may also normally serve to prevent the aggre-
gation of adjacent ﬁbrils into the types of composite
1764 Am. J. Hum. Genet. 66:1757–1765, 2000
ﬁbrils that are seen in cases of classical EDS and that
are shown here for patient P10 (see ﬁg. 4).
On the basis of the postulated role of the a1(V) chain
in the control of the diameter and the shape of hetero-
typic ﬁbrils, the mode whereby functional haploinsuf-
ﬁciency for COL5A1 leads to the outsized and aggre-
gated dermal collagen ﬁbrils in patients with EDS is
conceptually simple. However, mutant a1(V) and a2(V)
chains that have either exon skipping or glycine sub-
stitutions have dominant-negative effects that result in
abnormal dermal collagen ﬁbrils and classical EDS, by
means of less-apparent mechanisms (De Paepe et al.
1997; Burrows et al. 1998; Michalickova et al. 1998;
Richards et al. 1998). In either case, the presence of
abnormal heterotypic ﬁbrils correlates with marked
changes in the mechanical properties of many tissues in
which type V collagen genes are expressed. It is unclear
whether these altered mechanical characteristics reﬂect
changes in intermolecular cross-links or more global
alterations that are a response to variations in the
amount or structure of the relatively minor extracellular
component, type V collagen. The results presented in
this study indicate that more than one-third of cases of
classical EDS are likely to result from COL5A1 null
alleles.
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